Ascendis Pharma (ASND) Stock Forecast & Price Target

Compare

670 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ASND Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Ascendis

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$260.15

▲(23.59% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $260.15 with a high forecast of $325.00 and a low forecast of $220.00. The average price target represents a 23.59% change from the last price of $210.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","225":"$225","326":"$326","174.5":"$174.5","275.5":"$275.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$325.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":260.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$260.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$220.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,174.5,225,275.5,326],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.6,211.09230769230768,220.58461538461538,230.07692307692307,239.56923076923076,249.06153846153845,258.55384615384617,268.04615384615386,277.53846153846155,287.03076923076924,296.5230769230769,306.0153846153846,315.5076923076923,{"y":325,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.6,206.10384615384615,210.6076923076923,215.11153846153846,219.6153846153846,224.11923076923077,228.62307692307692,233.12692307692305,237.6307692307692,242.13461538461536,246.6384615384615,251.14230769230767,255.64615384615382,{"y":260.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.6,203.01538461538462,204.43076923076922,205.84615384615384,207.26153846153846,208.67692307692306,210.09230769230768,211.5076923076923,212.92307692307693,214.33846153846153,215.75384615384615,217.16923076923078,218.58461538461538,{"y":220,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$325.00

Average Price Target$260.15

Lowest Price Target$220.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yun Zhong

Wedbush

$220

Buy

4.52%

Upside

Reiterated

11/18/25

Buy Rating for Ascendis Pharma Driven by Promising TransCon CNP Developments in Achondroplasia Treatment

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

$255

Buy

21.15%

Upside

Initiated

11/17/25

Ascendis Pharma initiated with an Outperform at Wolfe ResearchAscendis Pharma initiated with an Outperform at Wolfe Research

Derek Archila

Wells Fargo

$297

Buy

41.10%

Upside

Reiterated

11/14/25

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

Luca Issi

RBC Capital

$240

Buy

14.02%

Upside

Reiterated

11/14/25

RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Yaron Werber

TD Cowen

$227→$325

Buy

54.40%

Upside

Reiterated

11/13/25

TD Cowen Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)

Maxwell Skor

Morgan Stanley

$250

Buy

18.77%

Upside

Reiterated

11/13/25

Morgan Stanley Reaffirms Their Buy Rating on Ascendis Pharma (ASND)Ascendis Pharma A/S Overweight; Price Target remains at 250.00.

Leland Gershell

Oppenheimer

$246

Buy

16.87%

Upside

Reiterated

11/13/25

Oppenheimer Remains a Buy on Ascendis Pharma (ASND)

Li Watsek

Cantor Fitzgerald

$254

Buy

20.67%

Upside

Reiterated

11/13/25

Cantor Fitzgerald Sticks to Their Buy Rating for Ascendis Pharma (ASND)

Tazeen Ahmad

Bank of America Securities

$242

Buy

14.97%

Upside

Reiterated

11/12/25

Strong Demand and Strategic Developments Drive Buy Rating for Ascendis Pharma

Martin Auster

Raymond James

$271

Buy

28.75%

Upside

Initiated

10/17/25

Ascendis Pharma initiated with a Strong Buy at Raymond JamesAscendis Pharma initiated with a Strong Buy at Raymond James

Joseph Schwartz

Leerink Partners

$225

Buy

6.89%

Upside

Reiterated

09/23/25

Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Eliana Merle

UBS

$307

Buy

45.85%

Upside

Reiterated

09/22/25

Ascendis Pharma's Market Leadership and Growth Potential in Chronic Hypoparathyroidism

Paul Choi

Goldman Sachs

$250

Buy

18.77%

Upside

Reiterated

09/05/25

Alex Thompson CFA

Stifel Nicolaus

$212→$254

Buy

20.67%

Upside

Reiterated

08/08/25

Stifel Nicolaus Sticks to Their Buy Rating for Ascendis Pharma (ASND)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yun Zhong

Wedbush

$220

Buy

4.52%

Upside

Reiterated

11/18/25

Buy Rating for Ascendis Pharma Driven by Promising TransCon CNP Developments in Achondroplasia Treatment

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

$255

Buy

21.15%

Upside

Initiated

11/17/25

Ascendis Pharma initiated with an Outperform at Wolfe ResearchAscendis Pharma initiated with an Outperform at Wolfe Research

Derek Archila

Wells Fargo

$297

Buy

41.10%

Upside

Reiterated

11/14/25

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

Luca Issi

RBC Capital

$240

Buy

14.02%

Upside

Reiterated

11/14/25

RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Yaron Werber

TD Cowen

$227→$325

Buy

54.40%

Upside

Reiterated

11/13/25

TD Cowen Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)

Maxwell Skor

Morgan Stanley

$250

Buy

18.77%

Upside

Reiterated

11/13/25

Morgan Stanley Reaffirms Their Buy Rating on Ascendis Pharma (ASND)Ascendis Pharma A/S Overweight; Price Target remains at 250.00.

Leland Gershell

Oppenheimer

$246

Buy

16.87%

Upside

Reiterated

11/13/25

Oppenheimer Remains a Buy on Ascendis Pharma (ASND)

Li Watsek

Cantor Fitzgerald

$254

Buy

20.67%

Upside

Reiterated

11/13/25

Cantor Fitzgerald Sticks to Their Buy Rating for Ascendis Pharma (ASND)

Tazeen Ahmad

Bank of America Securities

$242

Buy

14.97%

Upside

Reiterated

11/12/25

Strong Demand and Strategic Developments Drive Buy Rating for Ascendis Pharma

Martin Auster

Raymond James

$271

Buy

28.75%

Upside

Initiated

10/17/25

Ascendis Pharma initiated with a Strong Buy at Raymond JamesAscendis Pharma initiated with a Strong Buy at Raymond James

Joseph Schwartz

Leerink Partners

$225

Buy

6.89%

Upside

Reiterated

09/23/25

Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Eliana Merle

UBS

$307

Buy

45.85%

Upside

Reiterated

09/22/25

Ascendis Pharma's Market Leadership and Growth Potential in Chronic Hypoparathyroidism

Paul Choi

Goldman Sachs

$250

Buy

18.77%

Upside

Reiterated

09/05/25

Alex Thompson CFA

Stifel Nicolaus

$212→$254

Buy

20.67%

Upside

Reiterated

08/08/25

Stifel Nicolaus Sticks to Their Buy Rating for Ascendis Pharma (ASND)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+5.25%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +5.25% per trade.

3 Months

xxx

Success Rate

20/26 ratings generated profit

Average Return

+10.77%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +10.77% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

29/33 ratings generated profit

Average Return

+27.80%

reiterated a buy rating 11 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 87.88% of your transactions generating a profit, with an average return of +27.80% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+62.36%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +62.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ASND has received 33 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 260.15.

Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is -$0.10 with a range of -$3.01 to $0.42. The previous quarter’s EPS was -$1.16. ASND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $284.93M with a range of $261.47M to $296.49M. The previous quarter’s sales results were $249.64M. ASND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?

Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 260.15.

What is ASND’s upside potential, based on the analysts’ average price target?

Ascendis Pharma has 23.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ASND a Buy, Sell or Hold?

Ascendis Pharma has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ascendis Pharma’s price target?

The average price target for Ascendis Pharma is 260.15. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $325.00 ,the lowest forecast is $220.00. The average price target represents 23.59% Increase from the current price of $210.49.

What do analysts say about Ascendis Pharma?

Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of ASND?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ascendis Pharma (ASND) Stock Forecast & Price Target

ASND Analyst Ratings

ASND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ascendis Pharma

ASND Analyst Recommendation Trends

ASND Financial Forecast

ASND Earnings Forecast

ASND Sales Forecast

ASND Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts